enGene Therapeutics (ENGN) Share-based Compensation (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Share-based Compensation of $45.2 million for Q2 2026, up 1605.66% year-over-year from $2.6 million in Q2 2025, and up 1512.56% quarter-over-quarter from $2.8 million in Q1 2026.
enGene Therapeutics (ENGN) Share-based Compensation (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Share-based Compensation for 4 consecutive years, with $45.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Share-based Compensation rose 1605.66% year-over-year to $45.2 million; the TTM figure through Apr 2026 stood at $45.2 million (up 496.7% YoY), while the FY2025 annual figure was $30.7 million, up 38.91% from the prior year.
- Share-based Compensation improved to $45.2 million in Q2 2026 per ENGN's latest filing, from $2.8 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $45.2 million in Q2 2026 and bottomed at $20000.0 in Q1 2023.
- Historically, Share-based Compensation has averaged $6.7 million across 4 years, with a median of $1.9 million in 2024.
- On a YoY basis, Share-based Compensation climbed as much as 4815.38% in 2024 and fell as far as 50.63% in 2024.
- enGene Therapeutics' Share-based Compensation stood at $3.4 million in 2023, then slumped by 50.63% to $1.7 million in 2024, then jumped by 57.37% to $2.6 million in 2025, then surged by 1634.46% to $45.2 million in 2026.
- Business Quant data shows ENGN's Share-based Compensation at $45.2 million in Q2 2026, $2.8 million in Q1 2026, and $2.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | - |
| 10 | enGene Therapeutics | 125.16 Mn | 125.16 Mn | - | 45.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 45.20 Mn |
| Apr 30, 2026 | 45.20 Mn |
| Jan 31, 2026 | 2.80 Mn |
| Jan 31, 2026 | 2.80 Mn |
| Oct 31, 2025 | 2.61 Mn |
| Oct 31, 2025 | 2.61 Mn |
| Jul 31, 2025 | 30.10 Mn |
| Jul 31, 2025 | 30.10 Mn |
| Apr 30, 2025 | 2.65 Mn |
| Apr 30, 2025 | 2.65 Mn |
| Jan 31, 2025 | 1.81 Mn |
| Jan 31, 2025 | 1.81 Mn |
| Oct 31, 2024 | 1.66 Mn |
| Oct 31, 2024 | 1.66 Mn |
| Jul 31, 2024 | 1.46 Mn |
| Jul 31, 2024 | 1.46 Mn |
| Apr 30, 2024 | 1.92 Mn |
| Apr 30, 2024 | 1.92 Mn |
| Jan 31, 2024 | 291,000.00 |
| Jan 31, 2024 | 291,000.00 |